13 October 2022 - - US-based Torus Biosystems, a developer molecular in vitro diagnostics for point of care use, has appointed Nancy Hill as lead Independent director to the company's board of directors, the company said.

Hill will also serve as a member of the board's audit committee.

Hill has more than 30 years of experience in diagnostics, biotech, and device organizations.

She currently serves as Chief Product Officer at AltPep, a biotech start-up developing disease-modifying treatment and detection tools for amyloid diseases, including Alzheimer's and Parkinson's diseases.

Previously, she was executive vice president of Operations and Program Management and an officer at Adaptive Biotechnologies.

She was a member of the core executive team that grew the company from early start-up through IPO and beyond.

Prior to Adaptive, Hill led Sales and Marketing and was a member of the executive team at Spiration, Inc., a venture-backed medical device company that was acquired by Olympus.

She has also held senior leadership positions in Berlex Laboratories, Immunex Corp. and Amgen. Hill holds a Bachelor's degree from the University of Washington and an M.B.A. from the Kellogg School of Management at Northwestern University (Kellogg).

She is currently president of the Seattle Chapter of the Healthcare Businesswomen's Association, and a member of Kellogg's Alumni Council and Hawryluk Scholars Mentorship Council. Hill is a recipient of HBA's Leadership Excellence and Dedication Award.

Torus Biosystems, a spinout from the Harvard Wyss Institute for Biologically Inspired Engineering, is on a mission to transform patient lives by delivering breakthrough innovations in infectious disease diagnostics.

The company is currently developing syndromic testing solutions based on the integration of novel technologies, including qPCR and microarray technologies, that enable rapid, quantitative, and highly multiplexed detection of microbial pathogens and resistance genes that ultimately lead to improved patient outcomes.